Phase II Study of IMMU-132 Alone or in Combination With Carboplatin in Patients With Triple-Negative Breast Cancer
Status:
Withdrawn
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
This is a Phase II, open-label study that evaluates the safety and efficacy of IMMU-132 alone
and in combination with carboplatin in patients with triple-negative breast cancer. IMMU132
will be administered once-weekly for the first 2 weeks of 3-week treatment cycles. For those
patients assigned to also receive carboplatin, will receive it on the same schedules starting
30 minutes after the completion of IMMU-132 administration. Patients may receive up to a
maximum total of 8 cycles.